The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells.
| Inventor | Institute |
|---|---|
| Jacqueline Cordell | University of Oxford |
| SKU: | 151376 |
|---|---|
| Product description: | The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling. |
| Alternate name: | CD79b Molecule; CD79B Antigen (Immunoglobulin-Associated Beta); Immunoglobulin-Associated B29 Protein; B-Cell-Specific Glycoprotein B29; Ig-Beta |
| Conjugation: | Unconjugated |
| Isotype: | IgG2b |
| Immunogen: | Synthetic peptide representing the c-terminus from residue 215 of the murine B29 polypeptide. |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Cat. #: | 151376 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell signaling and signal transduction; Immunology |
| Application: | IHC ; WB |
| Target: | CD79b |
| Reactivity: | Human |
| Clone: | B29/123 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Hauser et al. 2013. Mol Immunol. 54(3-4):247-53. PMID: 23318223. Broad feedback inhibition of pre-B-cell receptor signaling components. Ouchida et al. 2010. J Immunol. 185(1):294-301. PMID: 20519653. A role for lysosomal-associated protein transmembrane 5 in the negative regulation of surface B cell receptor levels and B cell activation. Lankester et al. 1994. J Immunol. 152(5):2157-62. PMID: 8133032. Evidence for a direct physical interaction of membrane IgM, IgD, and IgG with the B29 gene product. Jones et al. 1993. J Immunol. 150(12):5429-35. PMID: 8515069. Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. Brouns et al. 1993. Eur J Immunol. 23(5):1088-97. PMID: 8477803. The structure of the mu/pseudo light chain complex on human pre-B cells is consistent with a function in signal transduction. Mason et al. 1992. Eur J Immunol. 22(10):2753-6. PMID: 1396979. The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.